The potential of psychedelics to be a part of treatments for depression, anxiety, post-traumatic stress disorder, drug dependency and eating disorders is being evaluated in numerous clinical trials. In 2018, the Food and Drug Administration marked psilocybin as a "breakthrough therapy," a designation that expedites the development of drugs that may be more effective than existing treatments. Senate Bill 519 would decriminalize the possession and non-commercial sharing of psychedelics by people age 21 or older. It would not permit the sale of psychedelics in government-sanctioned shops the way cannabis is allowed under state law, but sets up the framework for California to move toward regulating psychedelic drugs in the future. Psychologist Geoff Bathje of This site Adler University and Chicago's Sana Healing Collective, which consults with people who use psychedelics, said backers of the bill want to ensure equity by allowing a broad range of practitioners.